Your browser doesn't support javascript.
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano, Florian; Baudouin, Amandine; Zerbit, Jérémie; Toulemonde-Deldicque, Anne; Thomas-Schoemann, Audrey; Chevrier, Régine; Daouphars, Mikaël; Madelaine, Isabelle; Pourroy, Bertrand; Tournamille, Jean-François; Astier, Alain; Ranchon, Florence; Cazin, Jean-Louis; Bardin, Christophe; Rioufol, Catherine.
  • Slimano F; Department of Pharmacy, CHU Reims, France; Faculty of Pharmacy, Université de Reims Champagne-Ardenne, 51100 Reims, France. Electronic address: florianslimano@gmail.com.
  • Baudouin A; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France. Electronic address: amandine.baudouin@chu-lyon.fr.
  • Zerbit J; Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: jeremiezerbit@gmail.com.
  • Toulemonde-Deldicque A; Institut of Pharmacy, CHU Lille, 59000 Lille, France. Electronic address: anne.deldicque@gmail.com.
  • Thomas-Schoemann A; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France. Electronic address: schoemann.audrey@gmail.com.
  • Chevrier R; Department of Pharmacy, Jean Perrin Cancer Center, 63011 Clermont Ferrand, France. Electronic address: regine.chevrier@clermont.unicancer.fr.
  • Daouphars M; Department of Pharmacy, Henri Becquerel Cancer Center, 76038 Rouen, France. Electronic address: mikael.daouphars@chb.unicancer.fr.
  • Madelaine I; Department of Pharmacy, Saint Louis University Teaching Hospital, Assistance Publique - Hôpitaux de Paris, 75010 Paris, France. Electronic address: isabelle.madelaine@aphp.fr.
  • Pourroy B; Oncopharma Unit, La Timone University Teaching Hospital, Assistance Publique - Hôpitaux de Marseille, 13005 Marseille, France. Electronic address: bertrand.pourroy@ap-hm.fr.
  • Tournamille JF; Unité de Biopharmacie Clinique Oncologique, Pharmacie, CHU de Tours, 37000 Tours, France. Electronic address: jf.tournamille@sfpo.com.
  • Astier A; Department of Pharmacy, Henri Mondor University Hospitals, 94010 Créteil, France. Electronic address: prof.astier@gmail.com.
  • Ranchon F; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: florence.ranchon@chu-lyon.fr.
  • Cazin JL; Center of Pharmacology and Clinical Pharmacy in Oncology, Centre Oscar Lambret, 59020 Lille, France; Pharmacology and Clinical Pharmacy, Faculté de Pharmacie, Université de Lille, 59000 Lille, France. Electronic address: jean-louis.cazin@univ-lille.fr.
  • Bardin C; Department of Clinical Pharmacy, CHU Paris Centre Cochin, AP-HP, 75 014 Paris, France. Electronic address: christophe.bardin@aphp.fr.
  • Rioufol C; Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, Lyon, France; EA 3738 CICLY, UCBL1 Université de Lyon, Lyon, France. Electronic address: catherine.rioufol@chu-lyon.fr.
Cancer Treat Rev ; 88: 102063, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-634600
ABSTRACT
The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacy / Pneumonia, Viral / Coronavirus Infections / Medical Oncology / Neoplasms Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cancer Treat Rev Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmacy / Pneumonia, Viral / Coronavirus Infections / Medical Oncology / Neoplasms Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cancer Treat Rev Year: 2020 Document Type: Article